Analytical Data
-
Gene name
SSX3
- Application
-
Alternative Names
SSX3; Protein SSX3; Cancer/testis antigen 5.3; CT5.3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q99909
-
Expression Region
1-188 aa
-
AA Sequence
MNGDDTFARR PTVGAQIPEK IQKAFDDIAK YFSKEEWEKM KVSEKIVYVY MKRKYEAMTK LGFKAILPSF MRNKRVTDFQ GNDFDNDPNR GNQVQRPQMT FGRLQGIFPK IMPKKPAEEG NVSKEVPEAS GPQNDGKQLC PPGKPTTSEK INMISGPKRG EHAWTHRLRE RKQLVIYEEI SDPEEDDE
-
Molecular Weight
21.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SSX3, a member of the SSX gene family, is recognized as a cancer/testis (CT) antigen, which means it is typically expressed in testicular germ cells and various tumors but not in normal somatic tissues. This unique expression pattern makes SSX3 a potential target for immunotherapy in cancer treatment. Research into SSX3 has gained momentum as it is associated with various malignancies, including melanoma, breast cancer, and leukemias, prompting investigations into its role in tumor immune evasion and its potential as a biomarker. The reconstitution of SSX3 in a soluble recombinant protein form has become a focal point of study, as it allows for a deeper understanding of its immunogenic properties and interactions with immune cells. Investigating the structure and function of SSX3 not only aids in elucidating its biological role in cancer but also facilitates the development of vaccine strategies aimed at eliciting specific immune responses. By characterizing SSX3, researchers hope to advance the field of cancer immunotherapy and create novel approaches for targeted treatment, ultimately improving clinical outcomes for patients with cancers expressing this tumor-associated antigen.
